Screening for prostate cancer should help to detect malignancy at an early and potentially treatable stage. Serum psa has been used as a test for prostate cancer for over 20 years, but its practise is still very controversial worldwide.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Studies can demostrate good aspects for screening with psa: the overall mortality and especially the metastases at stage of primary diagnosis can be reduced. A relevant factor is measuring the serum psa in younger men aged 40-50 for a baseline to evaluate the individual risk of prostate cancer. Furthermore, it is important not to exclude patients because of their age of measuring the psa. The individual life expectancy should help to decide about its usefulness. This aspect is especially important in the face of an increasing life expectancy and fitness level at old age. Further studies are needed to publish a recommendation for psa-screening. In Germany, the PROBASE is a current study to research this topic.
Deutsche medizinische Wochenschrift (1946). 2015 Sep 24 [Epub]
Annabel Spek, Bernadett Szabados, Alexander Roosen, Christian Stief
Klinikum der Universität München, Urologische Klinik und Poliklinik. , Klinikum der Universität München, Urologische Klinik und Poliklinik. , Klinikum der Universität München, Urologische Klinik und Poliklinik. , Klinikum der Universität München, Urologische Klinik und Poliklinik.